Rahman Shah, Facc, Fscai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2106250/publications.pdf

Version: 2024-02-01

60 papers

410 citations

949033 11 h-index 19 g-index

60 all docs 60 docs citations

60 times ranked

734 citing authors

#	Article	IF	CITATIONS
1	A meta-analysis of optimal medical therapy with or without percutaneous coronary intervention in patients with stable coronary artery disease. Coronary Artery Disease, 2022, 33, 91-97.	0.3	5
2	Increased risk of stent thrombosis with use of a direct oral anticoagulant and a single antiplatelet agent after <scp>PCI</scp> : A metaâ€analysis. Catheterization and Cardiovascular Interventions, 2021, 98, E490-E492.	0.7	0
3	Letter by Shah Regarding Article, "Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials― Circulation, 2021, 143, e807-e808.	1.6	1
4	A Meta-analysis of Clinical Trials Evaluating the Impact of Bivalirudin-based Anticoagulation for Primary Percutaneous Coronary on Long-Term Mortality. Journal of Cardiovascular Pharmacology, 2021, 78, e40-e44.	0.8	2
5	A Meta-Analysis Comparing Aspirin Alone Versus Dual Antiplatelet Therapy for the Prevention of Venous Graft Failure Following Coronary Artery Bypass Surgery. Cardiovascular Revascularization Medicine, 2020, 21, 792-796.	0.3	11
6	Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia. American Journal of Cardiology, 2020, 134, 69-73.	0.7	64
7	A Man With a Sixth Wave in Electrocardiogram Results. JAMA Internal Medicine, 2020, 180, 1685.	2.6	O
8	Contrast-associated acute kidney injury. Quantitative Imaging in Medicine and Surgery, 2020, 10, 891-894.	1.1	6
9	Accuracy of fractional flow reserve during acute myocardial infarction. European Heart Journal, 2020, 41, 2597-2597.	1.0	2
10	Meta-Analysis of Optimal Revascularization Strategy for Patients With ST-Segment Elevation Myocardial Infarction and Multi-Vessel Coronary Artery Disease. American Journal of Cardiology, 2020, 129, 19-24.	0.7	2
11	Letter by Shah Regarding Article, "Effects of Percutaneous Coronary Intervention on Death and Myocardial Infarction Stratified by Stable and Unstable Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials― Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006788.	0.9	0
12	A Meta-Analysis of Aspirin for the Primary Prevention of Cardiovascular Diseases in the Context of Contemporary Preventive Strategies. American Journal of Medicine, 2019, 132, 1295-1304.e3.	0.6	16
13	An Updated Meta-Analysis Comparing Percutaneous Device Closure with Medical Therapy Alone for Patent Foramen Ovale in Patients with Cryptogenic Stroke. Cardiovascular Revascularization Medicine, 2019, 20, 926-927.	0.3	1
14	Drug-eluting stents versus bare-metal stents for saphenous vein graft interventions. Journal of Thoracic Disease, 2019, 11, S1257-S1260.	0.6	2
15	Postprocedure bivalirudin infusion for primary percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2019, 94, 900-901.	0.7	O
16	Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events. JAMA - Journal of the American Medical Association, 2019, 321, 2244.	3.8	3
17	The MATRIX trial. Lancet, The, 2019, 393, 1803.	6.3	5
18	Short-term versus long-term triple antithrombotic therapy for patients with coronary stents and requiring oral anticoagulation. Coronary Artery Disease, 2019, 30, 116-123.	0.3	0

#	Article	IF	CITATIONS
19	Bivalirudin with a postâ€procedure infusion versus heparin monotherapy for the prevention of stent thrombosis. Catheterization and Cardiovascular Interventions, 2019, 94, 210-215.	0.7	13
20	A Brief Meta-analysis of Oxygen Therapy for Normoxemic Patients with Acute Coronary Syndrome. American Journal of the Medical Sciences, 2019, 357, 268-270.	0.4	O
21	Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2019, 93, 241-247.	0.7	6
22	Bioresorbable polymer drug-eluting stents. Lancet, The, 2018, 391, 935-936.	6.3	3
23	Letter by Shah and Latham Regarding Article, "Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With the Guidelines-Heart Failure― Circulation, 2018, 138, 2303-2304.	1.6	O
24	Efficacy and Safety of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents With a Single Month of Dual Antiplatelet Therapy. JAMA Cardiology, 2018, 3, 1050.	3.0	26
25	A comprehensive metaâ€analysis of stem cell therapy for chronic angina. Clinical Cardiology, 2018, 41, 525-531.	0.7	5
26	A comprehensive metaâ€analysis of randomized controlled trials comparing drugâ€eluting stents with bareâ€metal stents in saphenous vein graft interventions. Catheterization and Cardiovascular Interventions, 2018, 92, 1229-1236.	0.7	3
27	Meta-Analysis Comparing Coronary Artery Bypass Grafting to Drug-Eluting Stents and to Medical Therapy Alone for Left Main Coronary Artery Disease. American Journal of Cardiology, 2017, 120, 63-68.	0.7	12
28	Optical coherence tomography-guided PCI. Lancet, The, 2017, 389, 1607.	6.3	0
29	Letter by Shah Regarding Article, "Thrombus Aspiration in ST-Segment–Elevation Myocardial Infarction: An Individual Patient Meta-Analysis: Thrombectomy Trialists Collaboration― Circulation, 2017, 135, e1101-e1102.	1.6	1
30	Meta-Analysis of the Relative Efficacy and Safety of OralÂP2Y12 Inhibitors in Patients With Acute CoronaryÂSyndrome. American Journal of Cardiology, 2017, 119, 1723-1728.	0.7	28
31	Mortality and operator experience with vascular access for percutaneous coronary intervention in patients with acute coronary syndromes: A pairwise and network meta-analysis of randomized controlled trials. International Journal of Cardiology, 2017, 248, 114-119.	0.8	7
32	Bioresorbable vascular scaffolds and late lumen loss. Lancet, The, 2017, 389, 1796-1797.	6.3	0
33	Effect of postâ€primary percutaneous coronary intervention bivalirudin infusion on net adverse clinical events and mortality: A comprehensive pairwise and network metaâ€analysis of randomized controlled trials. Catheterization and Cardiovascular Interventions, 2017, 90, 196-204.	0.7	8
34	Highâ€volume forced diuresis with matched hydration using the RenalGuard System to prevent contrastâ€induced nephropathy: A metaâ€analysis of randomized trials. Clinical Cardiology, 2017, 40, 1242-1246.	0.7	22
35	Duration of triple antithrombotic therapy and outcomes among patients undergoing percutaneous coronary intervention. Cardiovascular Diagnosis and Therapy, 2017, 7, S66-S68.	0.7	1
36	Contrast use in relation to the arterial access site for percutaneous coronary intervention: A comprehensive meta-analysis of randomized trials. World Journal of Cardiology, 2017, 9, 378.	0.5	4

#	Article	lF	Citations
37	Complete versus culprit-only revascularisation for ST-segment elevation myocardial infarction. Heart, 2016, 102, 1335.2-1335.	1.2	1
38	Stroke risk from manual aspiration thrombectomy during primary percutaneous coronary intervention: An updated comprehensive meta-analysis of randomized controlled trials. International Journal of Cardiology, 2016, 222, 636-638.	0.8	O
39	Meta-Analysis Comparing Complete Revascularization Versus Infarct-Related Only Strategies for Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease. American Journal of Cardiology, 2016, 118, 1466-1472.	0.7	25
40	Invasive strategy in acute coronary syndrome. Lancet, The, 2016, 387, 2503.	6.3	1
41	Optimum technique to reduce risk of stent thrombosis. Lancet, The, 2016, 388, 127.	6.3	3
42	A Patient with Metastatic Small-Cell Lung Cancer and Giant Right Ventricular Mass. Echocardiography, 2016, 33, 491-493.	0.3	3
43	Effect of Post–Primary Percutaneous Coronary Intervention Bivalirudin InfusionÂon Acute Stent Thrombosis. JACC: Cardiovascular Interventions, 2016, 9, 1313-1320.	1.1	24
44	An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention. American Heart Journal, 2016, 171, 14-24.	1.2	46
45	Diaphragmatic stimulation caused by cardiac resynchronization treatment. Cmaj, 2016, 188, E239-E239.	0.9	8
46	An Elderly Patient With Palpitation and a Negative Nuclear Stress Test Result. JAMA Internal Medicine, 2016, 176, 542.	2.6	0
47	An 81-Year-Old Man With an Abnormal Right-Sided Heart Shadow on Chest Radiograph. Chest, 2015, 147, e52-e55.	0.4	O
48	Wide Complex Tachycardia in a Patient With a Family History of Sudden Death. JAMA Internal Medicine, 2015, 175, 128.	2.6	0
49	Bivalirudin versus heparin use for patients undergoing PPCI. Lancet, The, 2015, 385, 2045.	6.3	2
50	Radial versus femoral access for cardiac catheterisation. Lancet, The, 2015, 386, 2392-2393.	6.3	7
51	Dual antiplatelet treatment after stenting. Lancet, The, 2015, 385, 326.	6.3	O
52	Ticagrelor as an alternative in clopidogrel-associated neutropenia. Platelets, 2015, 26, 80-82.	1.1	14
53	\hat{l}^2 blockers in patients with heart failure and atrial fibrillation. Lancet, The, 2015, 385, 1618.	6.3	4
54	Cocaine-Induced Acute Aortic Dissection. Journal of Emergency Medicine, 2015, 49, e87-e89.	0.3	7

#	Article	IF	CITATIONS
55	Lesson of the month 1: Broken heart in the intensive care unit. Clinical Medicine, 2014, 14, 447-448.	0.8	1
56	Linagliptin for elderly patients with type 2 diabetes. Lancet, The, 2014, 383, 306-307.	6.3	0
57	Dangerous Cold Beverages: A Case of Swallow Syncope. American Journal of Medicine, 2014, 127, e3-e4.	0.6	3
58	New oral anticoagulants in patients with atrial fibrillation. Lancet, The, 2014, 384, 23-24.	6.3	1
59	Myocardial Ischemic Events in â€~Real World' Patients Treated with Dabigatran. American Journal of Medicine, 2014, 127, e19.	0.6	O
60	Renal denervation for resistant hypertension—the Symplicity HTN-1 study. Lancet, The, 2014, 383, 1885.	6.3	1